ARGO

Strengthening Financial Security: Advanced Fraud Solutions and ARGO Unite Against Rising Check Fraud

Retrieved on: 
Monday, October 30, 2023

HIGH POINT, N.C., Oct. 30, 2023 /PRNewswire/ -- Advanced Fraud Solutions (AFS), a leading provider of real-time deposit fraud detection solutions, is thrilled to announce its strategic partnership with ARGO, an industry leader in technology solutions for the financial services and healthcare sectors.

Key Points: 
  • HIGH POINT, N.C., Oct. 30, 2023 /PRNewswire/ -- Advanced Fraud Solutions (AFS), a leading provider of real-time deposit fraud detection solutions, is thrilled to announce its strategic partnership with ARGO, an industry leader in technology solutions for the financial services and healthcare sectors.
  • The collaboration will integrate AFS' TrueChecks®, the industry's premier check fraud database, into ARGO's OASIS™ (Optimized Assessment of Suspicious Items) Fraud Prevention Suite.
  • The urgency of this partnership is underscored by recent alarming statistics about the prevalence of check fraud.
  • According to data from the Financial Crimes Enforcement Network (FCEN), a unit of the U.S. Treasury Department, check fraud has tripled since pre-pandemic levels.

Hong Kong’s COA and ARGO Earn Spots in the World’s 50 Best Bars 2023 List

Retrieved on: 
Tuesday, October 24, 2023

The annual list of The World’s 50 Best Bars, sponsored by Perrier, was unveiled as part of a live awards ceremony in Singapore on Tuesday, October 17, 2023.

Key Points: 
  • The annual list of The World’s 50 Best Bars, sponsored by Perrier, was unveiled as part of a live awards ceremony in Singapore on Tuesday, October 17, 2023.
  • View the full release here: https://www.businesswire.com/news/home/20231024861446/en/
    Inspired by Mexico’s drinking dens, COA serves unique cocktails like their Mole Negroni (Photo: Business Wire)
    The World’s 50 Best Bars 2023 features establishments from 28 cities, highlighting venues that specialize in exceptional atmosphere, service, and drinks.
  • Hong Kong was represented by COA at No.
  • The destination gained four ranked places in the 1-100 list overall, ensuring its vibrant bar scene is well-recognized globally.

Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress

Retrieved on: 
Wednesday, October 4, 2023

In June 2023, MoonLake announced positive topline 12-week Phase 2 MIRA trial results , achieving a landmark milestone as the first placebo-controlled randomized trial in HS to report positive top-line results using HiSCR75 as the primary endpoint.

Key Points: 
  • In June 2023, MoonLake announced positive topline 12-week Phase 2 MIRA trial results , achieving a landmark milestone as the first placebo-controlled randomized trial in HS to report positive top-line results using HiSCR75 as the primary endpoint.
  • Professor Brian Kirby MD, FRCPI, Charles Department of Dermatology, St. Vincent’s University Hospital and Charles Institute of Dermatology, University College Dublin, Dublin, Ireland will be presenting the results in a late-breaking news presentation, details of which are included below.
  • Date and time: Wednesday, 11 October; session 14.15 - 17.30 CEST, presentation 16.15 - 16.30 CEST
    Presentation title: Efficacy and safety of the IL-17A- and IL-17F-inhibiting Nanobody® sonelokimab in patients with active, moderate-to-severe hidradenitis suppurativa: Results from the global, randomized, double-blind, placebo-controlled Phase 2 MIRA trial
    The 24-week Phase 2 MIRA trial data for Nanobody® sonelokimab in hidradenitis suppurativa is anticipated imminently.
  • In addition, top-line 12-week results for MoonLake’s Phase 2 ARGO trial with Nanobody® sonelokimab in psoriatic arthritis (PsA) are expected in the first half of November 2023, ahead of the American College of Rheumatology Conference, November 10-15.

MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11

Retrieved on: 
Wednesday, September 6, 2023

ZUG, Switzerland, September 6, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a Capital Markets Day for investors and analysts on Monday, September 11.

Key Points: 
  • ZUG, Switzerland, September 6, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a Capital Markets Day for investors and analysts on Monday, September 11.
  • The live webcast will be viewable from 11:30 am – 13:00 pm EDT/16:30 pm – 18:00 BST/17:30 – 19:00 pm CEST.
  • Registration for the webcast is open and accessible online here .
  • The MoonLake team will discuss the evolving psoriatic arthritis (PsA) market and expectations ahead of the top-line 12-week results from the Phase 2 ARGO trial which is expected in the first half of November 2023.

Greg Chilson to Serve as President of Argo Surety

Retrieved on: 
Monday, August 21, 2023

Argo Group International Holdings, Ltd. (NYSE: ARGO) ("Argo" or the "company") today announced Greg Chilson as president of Argo Surety, effective September 1.

Key Points: 
  • Argo Group International Holdings, Ltd. (NYSE: ARGO) ("Argo" or the "company") today announced Greg Chilson as president of Argo Surety, effective September 1.
  • “Greg joins the company with a tremendous amount of industry experience as we look to build on Argo Surety’s track record as a very profitable, growth-oriented business,” said Argo’s President of U.S. Insurance, Jessica Snyder.
  • Chilson joins Argo from RLI Insurance Company where he led the surety business and held various roles during his 27-year tenure.
  • Most recently, he served as vice president and director, Enterprise Risk Management at Markel Surety.

MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, August 10, 2023

Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “This quarter has been transformational for MoonLake.

Key Points: 
  • Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “This quarter has been transformational for MoonLake.
  • Second Quarter 2023 Financial Highlights:
    On June 30, 2023, MoonLake closed a public offering of 8,000,000 Class A Ordinary Shares at a public offering price of $50.00 per Share.
  • Research and development expenses for the quarter ended June 30, 2023, were $8.7 million, compared to $7.4 million in the previous quarter.
  • General and administrative expenses for the quarter ended June 30, 2023, were $4.5 million, compared to $5.5 million in the previous quarter.

Argo Group Schedules Second Quarter 2023 Earnings Release

Retrieved on: 
Tuesday, July 25, 2023

Argo Group International Holdings, Ltd. (“Argo”) (NYSE: ARGO) announced today it will release second quarter 2023 financial results after the close of U.S. financial markets on Monday, August 7, 2023.

Key Points: 

Argo Group International Holdings, Ltd. (“Argo”) (NYSE: ARGO) announced today it will release second quarter 2023 financial results after the close of U.S. financial markets on Monday, August 7, 2023.

MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts  

Retrieved on: 
Tuesday, July 25, 2023

MoonLake also announced a Capital Markets Day to be held in New York at NASDAQ, including a virtual webcast format, on September 11th 2023.

Key Points: 
  • MoonLake also announced a Capital Markets Day to be held in New York at NASDAQ, including a virtual webcast format, on September 11th 2023.
  • Jorge Santos da Silva, PhD, Founder and Chief Executive Officer at MoonLake, said: “ARGO is MoonLake’s second trial to have achieved faster completion of recruitment and randomization than expected.
  • Reaching this stage well ahead of schedule for active psoriatic arthritis is an encouraging reflection of the interest in our clinical development programs.
  • The trial also includes adalimumab, the current standard of care for PsA, as an active reference arm.

Alliance of Responsible Gun Ownership (ARGO) Launches on July 4th Independence Day

Retrieved on: 
Tuesday, July 4, 2023

Washington, D.C.--(Newsfile Corp. - July 4, 2023) - Alliance of Responsible Gun Ownership (ARGO) is proud to announce its official launch on Independence Day, symbolizing its commitment to freedom, safety, and dialogue.

Key Points: 
  • Washington, D.C.--(Newsfile Corp. - July 4, 2023) - Alliance of Responsible Gun Ownership (ARGO) is proud to announce its official launch on Independence Day, symbolizing its commitment to freedom, safety, and dialogue.
  • ARGO says it is actively lobbying state and federal legislators on both sides of the aisle to promote moderate gun policies.
  • To view an enhanced version of this graphic, please visit:
    ARGO's mission is to empower responsible gun owners, reshape the current narrative surrounding guns in America, reduce gun violence, advocate for a sensible and practical legal framework surrounding firearms, educate gun owners and non-owners alike in responsible gun ownership, and protect the inherent constitutional rights of all Americans.
  • ARGO welcomes both gun owners and non-owners who share its vision of building a safe society while exercising natural rights.

Four Seasons Celebrates Global Michelin Star Leadership with 32 Stars Across its Dynamic Restaurant Portfolio

Retrieved on: 
Wednesday, June 7, 2023

TORONTO, June 7, 2023 /PRNewswire/ -- Building upon a longstanding history of culinary excellence, Four Seasons has once again maintained its leadership position of holding the most Michelin stars of any single luxury hospitality brand with 32 stars across 25 restaurants in 19 hotels and resorts globally. Even more notable is that 27 of these stars were awarded to original restaurant concepts, independently owned and operated by Four Seasons. This latest recognition sits among the company's host of international restaurant and bar accolades, which include 50 Best, La Liste, Gault Millau, Wine Spectator and more.

Key Points: 
  • Even more notable is that 27 of these stars were awarded to original restaurant concepts, independently owned and operated by Four Seasons.
  • Several Four Seasons restaurants gained their first Michelin stars in this past year's Guides.
  • La Dame de Pic – Le 1920* at Four Seasons Hotel Megève and Le Cap* at Grand-Hôtel du Cap-Ferrat, A Four Seasons Hotel also retained their stars, maintaining Four Seasons longstanding leadership within the French Michelin Guide.
  • Four Seasons celebrates additional Michelin-starred outlets across its portfolio with Pelagos * at Four Seasons Astir Palace Hotel Athens; Yu Ting Yuan * at Four Seasons Hotel Bangkok at Chao Phraya River; Mio* and Cai Yi Xuan* at Four Seasons Hotel Beijing; Il Palagio* at Four Seasons Hotel Firenze; Il Lago* at Four Seasons Hotel des Bergues Geneva; Yu Yue Heen* at Four Seasons Hotel Guangzhou; CURA* at Four Seasons Hotel Ritz Lisbon; Zi Yat Heen* at Four Seasons Hotel Macao, Cotai Strip and est * at Four Seasons Hotel Tokyo at Otemachi.